RxDoctor Payments Data

Naim Salloum, MD

Radiation Oncology · Hattiesburg, MSNPI 1205870656

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,767 of the $2,046 with a category attached, or 86.4%. It is spread thinly across 16 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $499, 2.5 times the $201 reported in 2019.

$2,046in general payments, 2019–2025

Across 84 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$396
  • Johnson & Johnson$366
  • Astellas Pharma US Inc$316
  • Myriad Genetic Laboratories, Inc.$315
  • Novartis$211
  • Boston Scientific$89
  • plus $353 from 10 others

What the payments were for

  • Food & beverage$1,76786%
  • Education$27914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,046 in reported general payments places this provider in the 75th percentile of 36 radiation oncology providers in Mississippi.

See all radiation oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$611,172
Medicare patients
337
Services billed
7,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide40$580,373
Abiraterone Acetate12$30,577
Sucralfate21$1,568
Hydrocortisone34$489
Dexamethasone20$405
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$380
Fluconazole17$263
Tamsulosin Hcl42$238
Ondansetron OdtOndansetron13$214
Ondansetron Hcl26$151
Silver Sulfadiazine11$117
Famotidine19$89
Prednisone13$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$366$580,37340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 36 radiation oncology providers in Mississippi.

Other radiation oncology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →